Patient P-02059
Therapy response
Unstable
Tolerance
Stable
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
81%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S03
- Day 63 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 68 SC-12 recommended — Supportive Compound SC-12
- Day 69 Patient accepted — Started SC-12 in the companion
- Day 75 GI symptom burden −14% vs expected — Supportive Compound SC-12
- Day 79 GI-04 recommended — GI Support Protocol GI-04
- Day 80 Patient declined — Not now
- Day 81 Tolerance state changed — Unstable → Improving
- Day 81 ME-01 recommended — Monitoring Escalation ME-01
- Day 82 Patient accepted — Started ME-01 in the companion
- Day 85 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 63.
Primary contributors, last 14 days
- Nutritional resilience-5
- GI instability-3
- Toxicity+3
- Treatment adherence+2
What helped?
- Supportive Compound SC-12Day 68Result: symptom burden −14%
- GI Support Protocol GI-04Day 79Declined by patient
- Monitoring Escalation ME-01Day 81Result: deterioration detected before clinical escalation
LIFE OS recommendation
GI Support Protocol GI-04
92%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 86% showed improvement
- median effect visible after 8 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓80
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 63 and rising
- Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↓50
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 62
- Drug metabolism and exposure ↑20
- BloodToxicity index 45
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Intermediate metabolizerExpected exposure
- GLP1R rs6923761 AAltered receptor sensitivity
Microbiome
Shannon diversity 3.1 · butyrate capacity 29/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiLow
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 49 ms
- Sleep
- 6.7 h
- Steps
- 6,459
- Resting HR
- 68 bpm
Daily log: GI score 63, nutritional resilience 36, adherence 47.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02326 | 49% | S18 | NP-02 | improved | 44 |
| P-02628 | 49% | S14 | SC-12 | improved | 47 |
| P-02657 | 49% | S14 | — | — | 42 |
| P-02224 | 48% | S14 | NP-02 | no change | 33 |
| P-02546 | 47% | S20 | NP-02 | improved | 40 |
| P-02018 | 46% | S01 | GI-04 | improved | 46 |
| P-02253 | 45% | S14 | NP-02 | no change | 41 |
| P-02316 | 45% | S14 | GI-04 | improved | 51 |
| P-02506 | 45% | S14 | SC-12 | no change | 32 |
| P-02516 | 45% | S14 | SC-12 | improved | 51 |
| P-02348 | 44% | S14 | GI-04 | improved | 49 |
| P-02535 | 44% | S14 | SC-12 | improved | 50 |